Clinical trial
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
NCT00088140 · Conatus Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00088140 |
|---|---|
| Title | A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients |
| Official title | A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients |
| Lead sponsor | Conatus Pharmaceuticals Inc., Industry |
| Collaborators | Idun Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | IDN-6556, Placebo |
| Enrollment | 204 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jul 21, 2004 |
| Last update posted | Aug 13, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: